MHRA approves Vyjuvek for dystrophic epidermolysis bullosa treatment, offering new hope for patients with this rare genetic condition. Learn more ...
Discover how the Access Consortium's new pathway accelerates medicine approval across borders, benefiting patients and pharmaceutical companies alike. ...